Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Cite this paper

@inproceedings{Klein2017CergutuzumabA, title={Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines}, author={Christian Klein and Inja Waldhauer and Valeria Gonzalez Nicolini and Anne Freimoser-Grundschober and Tapan Kumar Nayak and Danielle J. Vugts and Claire Dunn and Marije Bolijn and Joerg Benz and Martine Stihle and Sabine Lang and Michaele Roemmele and Thomas Hofer and Erwin van Puijenbroek and David Wittig and Samuel Moser and Oliver Ast and Peter Bruenker and Ingo H. Gorr and Sebastian Neumann and Maria Cristina de Vera Mudry and Heather J. Hinton and Flavio Crameri and Jose Saro and Stefan Evers and Christian A. Gerdes and Marina Bacac and Guus A. M. S. van Dongen and Ekkehard Moessner and Pablo Uma{\~n}a}, booktitle={Oncoimmunology}, year={2017} }